Skip to main content

Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.

Publication ,  Journal Article
Bachmann, KN; Roumie, CL; Wiese, AD; Grijalva, CG; Buse, JB; Bradford, R; Zalimeni, EO; Knoepp, P; Dard, S; Morris, HL; Donahoo, WT; Fanous, N ...
Published in: Pharmacol Res Perspect
October 2020

We used electronic medical record (EMR) data in the National Patient-Centered Clinical Research Network (PCORnet) to characterize "real-world" prescription patterns of Type 2 diabetes (T2D) medications. We identified a retrospective cohort of 613,203 adult patients with T2D from 33 datamarts (median patient number: 12,711) from 2012 through 2017 using a validated computable phenotype. We characterized outpatient T2D prescriptions for each patient in the 90 days before and after cohort entry, as well as demographics, comorbidities, non-T2D prescriptions, and clinical and laboratory variables in the 730 days prior to cohort entry. Approximately half of the individuals in the cohort were females and 20% Black. Hypertension (60.3%) and hyperlipidemia (50.5%) were highly prevalent. Most patients were prescribed either a single T2D drug class (42.2%) or had no evidence of a T2D prescription in the EMR (42.4%). A smaller percentage was prescribed multiple T2D drug types (15.4%). Among patients prescribed a single T2D drug type, metformin was the most common (42.6%), followed by insulin (18.2%) and sulfonylureas (13.9%). Newer classes represented approximately 13% of single T2D drug type prescriptions (dipeptidyl peptidase-4 inhibitors [6.6%], glucagon-like peptide-1 receptor agonists [2.5%], thiazolidinediones [2.0%], and sodium-glucose cotransporter-2 inhibitors [1.6%]). Among patients prescribed multiple T2D drug types, the most common combination was metformin and sulfonylureas (63.5%). Metformin-based regimens were highly prevalent in PCORnet's T2D population, whereas newer agents were prescribed less frequently. PCORnet is a novel source for the potential conduct of observational studies among patients with T2D.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pharmacol Res Perspect

DOI

EISSN

2052-1707

Publication Date

October 2020

Volume

8

Issue

5

Start / End Page

e00637

Location

United States

Related Subject Headings

  • United States
  • Thiazolidinediones
  • Sulfonylurea Compounds
  • Sodium-Glucose Transporter 2 Inhibitors
  • Retrospective Studies
  • Patient-Centered Care
  • Middle Aged
  • Metformin
  • Male
  • Insulin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bachmann, K. N., Roumie, C. L., Wiese, A. D., Grijalva, C. G., Buse, J. B., Bradford, R., … Chakkalakal, R. J. (2020). Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. Pharmacol Res Perspect, 8(5), e00637. https://doi.org/10.1002/prp2.637
Bachmann, Katherine N., Christianne L. Roumie, Andrew D. Wiese, Carlos G. Grijalva, John B. Buse, Robert Bradford, Emily O. Zalimeni, et al. “Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.Pharmacol Res Perspect 8, no. 5 (October 2020): e00637. https://doi.org/10.1002/prp2.637.
Bachmann KN, Roumie CL, Wiese AD, Grijalva CG, Buse JB, Bradford R, et al. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. Pharmacol Res Perspect. 2020 Oct;8(5):e00637.
Bachmann, Katherine N., et al. “Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.Pharmacol Res Perspect, vol. 8, no. 5, Oct. 2020, p. e00637. Pubmed, doi:10.1002/prp2.637.
Bachmann KN, Roumie CL, Wiese AD, Grijalva CG, Buse JB, Bradford R, Zalimeni EO, Knoepp P, Dard S, Morris HL, Donahoo WT, Fanous N, Fonseca V, Katalenich B, Choi S, Louzao D, O’Brien E, Cook MM, Rothman RL, Chakkalakal RJ. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. Pharmacol Res Perspect. 2020 Oct;8(5):e00637.

Published In

Pharmacol Res Perspect

DOI

EISSN

2052-1707

Publication Date

October 2020

Volume

8

Issue

5

Start / End Page

e00637

Location

United States

Related Subject Headings

  • United States
  • Thiazolidinediones
  • Sulfonylurea Compounds
  • Sodium-Glucose Transporter 2 Inhibitors
  • Retrospective Studies
  • Patient-Centered Care
  • Middle Aged
  • Metformin
  • Male
  • Insulin